Ohio Lumex, a recognized leader in analytical solutions, is proud to announce a new partnership with German biotechnology company Dynamic42. Effective immediately, Ohio Lumex will serve as the exclusive distributor of Dynamic42’s innovative organ-on-chip technology in the United States.
Dynamic42 and Heinrich Heine University have developed a tumour-on-a-chip model that replicates the microenvironment of pancreatic ductal adenocarcinoma (PDAC). This 3D model allows for realistic drug testing and could accelerate the development of personalized therapies.
Dynamic42, in collaboration with ESQlabs, Bayer, and the Placenta Lab, has developed an innovative three-organ system with the potential to reduce animal testing in pharmaceutical research.
Improving people’s lives with innovative technologies. This was the goal that Jena-based Dynamic42 had in mind 18 months ago when they launched a project – funded as part of the Sanofi iDEA-iTECH Award Program.
We are excited to welcome Amélie Marie Paillereau to the Dynamic42 science team. Amélie started in April with us for a 12-month-long Master thesis, focusing on perfused breast and pancreatic cancer-on-chip models to study the impact of the tumor microenvironment on immune cell invasion.
The RUBIN Alliance “ATHANA” (antifungal therapy approaches with nanoparticle-based targeting of drugs) is developing innovative therapeutic approaches for the treatment of infectious diseases, in particular fungal infections.
A first-of-its-kind collaboration in the consumer health industry is developing a platform aimed at reducing or replacing animal testing using “organ-on-chip” (OoC) technology and interactive computational software.